Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05108428 · ClinicalTrials.gov registry record · Early Phase 1

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

A Early Phase 1 study of Rectal Adenocarcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Active
Registry status
Early Phase 1
Development phase
20
Enrollment target
1
Study location

NCT05108428: Active Early Phase 1 study of Rectal Adenocarcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

NCT05108428 is a Early Phase 1 study of Rectal Adenocarcinoma that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 20 participants, below the 123-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05108428, a Early Phase 1 study of Rectal Adenocarcinoma, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to determine the feasibility of using magnetic resonance imaging (MRI)-guided adaptive chemoradiation therapy to improve response to treatment.

Primary Outcome

Investigators will demonstrate if MRI guided dose-adaptation based on MR morphologic objective measurements during primary chemoradiation is feasible. Feasibility will be recorded for each patient as an indicator variable (1=feasible; 0=not feasible)

Conditions Studied

Interventions

  • DRUG Capecitabine
  • RADIATION Radiation Therapy
  • DRUG FOLFOX regimen

Study Locations (1)

Florida

  • Moffitt Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-12-23
Est. Completion 2026-10
Phase Early Phase 1

What the registry record for NCT05108428 still lists

NCT05108428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 123-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine is the first listed.

NCT05108428 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05108428 about?

NCT05108428 is a clinical study titled "Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma". The purpose of the study is to determine the feasibility of using magnetic resonance imaging (MRI)-guided adaptive chemoradiation therapy to improve response to treatment.

What is the current status of trial NCT05108428?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2021-12-23. Estimated completion is 2026-10.

What conditions does trial NCT05108428 study?

This clinical trial studies the following conditions: Rectal Adenocarcinoma.

What interventions are being tested in trial NCT05108428?

The interventions under investigation include: Capecitabine (DRUG), Radiation Therapy (RADIATION), FOLFOX regimen (DRUG).

Who is sponsoring clinical trial NCT05108428?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05108428 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rectal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05108428's enrollment target sits among peer trials

20 16th of 17 higher than 1 of 17 other Rectal Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rectal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT05108428, the US trial registry maintained by the National Library of Medicine. NCT05108428 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.